Silexion Therapeutics (SLXN) Stock Overview
A biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
SLXN Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Silexion Therapeutics Corp Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.67 |
| 52 Week High | US$223.60 |
| 52 Week Low | US$2.31 |
| Beta | -0.33 |
| 1 Month Change | -11.05% |
| 3 Month Change | -76.17% |
| 1 Year Change | -96.71% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| SLXN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.9% | -2.9% | -2.8% |
| 1Y | -96.7% | 26.6% | 22.8% |
Return vs Industry: SLXN underperformed the US Biotechs industry which returned 26.9% over the past year.
Return vs Market: SLXN underperformed the US Market which returned 23.5% over the past year.
Price Volatility
| SLXN volatility | |
|---|---|
| SLXN Average Weekly Movement | 33.5% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SLXN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SLXN's weekly volatility has increased from 21% to 33% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 14 | Ilan Hadar | silexion.com |
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.
Silexion Therapeutics Corp Fundamentals Summary
| SLXN fundamental statistics | |
|---|---|
| Market cap | US$1.96m |
| Earnings (TTM) | -US$12.91m |
| Revenue (TTM) | n/a |
Is SLXN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLXN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.91m |
| Earnings | -US$12.91m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -30.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 533.7% |
How did SLXN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/07 11:45 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Silexion Therapeutics Corp is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Theodore O'Neill | Litchfield Hills Research, LLC |
| Jason McCarthy | Maxim Group |
| Nazibur Rahman | Maxim Group |